Power System Protection and Control
ISSN:1674-3415

MICROBIOME-BASED NUTRITIONAL INTERVENTIONS: MECHANISMS, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES OF PREBIOTICS, PROBIOTICS, AND SYNBIOTICS

Rajani Nallanagula[1], Kimeera Ambati[2], Santhi Sree Sunkara[2], S.V. Sumalatha[3], P.R. Sougandhi[4], Amineni Umamaheswari[5]

[1]Professor, Dept. of Home Science, Sri Padmavati Mahila Visvavidyalayam, Tirupati,
[2] Assistant Professor, Dept. of Home Science, Sri Padmavati Mahila Visvavidyalayam, Tirupati,
[3]Project Assistant, Dept. of Home Science, Sri Padmavati Mahila Visvavidyalayam, Tirupati,
[4]SRF, PM-USHA-Research and Development, Sri Padmavati Mahila Visvavidyalayam, Tirupati
[5]Professor, Dept. of Bioinformatics, Sri Venkateswara Institute of Medical Sciences, Tirupati.
Corresponding Authors -*kimeeraa@gmail.com
**rajani.nallanagula@gmail.com

Received: 25/02/2026 **Revised**: 10/03/2026 **Accepted**: 21/04/2026

***ABSTRACT*:**

The human gut microbiota, comprising more than 10^{14} microorganisms, plays a crucial role in regulating host metabolism, immune responses, and neurological functions. Growing evidence over the past decade has highlighted the importance of dietary interventions targeting gut microbiota for the prevention and management of chronic diseases. Prebiotics, probiotics, and synbiotics have emerged as promising functional food components capable of modulating microbial composition and activity to promote human health. Prebiotics are selectively fermentable substrates that stimulate the growth of beneficial bacteria, while probiotics are live microorganisms that confer health benefits when consumed in adequate amounts. Synbiotics combine both components to achieve synergistic effects by enhancing microbial survival and metabolic activity in the gastrointestinal tract.

Recent experimental and clinical studies demonstrate that these microbiota-targeted interventions improve gastrointestinal health, strengthen intestinal barrier integrity, and regulate immune responses through mechanisms such as short-chain fatty acid production, modulation of inflammatory cytokines, and enhancement of mucosal immunity. Furthermore, emerging evidence links prebiotics, probiotics, and synbiotics to improved metabolic outcomes, including better glycemic control, lipid metabolism, and body weight regulation. The microbiota–gut–brain axis has also attracted increasing attention, suggesting that microbial modulation may influence cognitive function, mood, and stress responses through neuroendocrine and immunological pathways.

Despite promising findings, variations in microbial strains, dosage, host microbiome composition, and study design present challenges in translating research outcomes into standardized dietary recommendations. Future research integrating metagenomics, metabolomics, and personalized nutrition approaches may enable more precise microbiome-targeted therapies. Overall, prebiotics, probiotics, and synbiotics represent innovative nutritional strategies for promoting gut health and preventing chronic non-communicable diseases.

Keywords: *Gut microbiota; Prebiotics; Probiotics; Synbiotics; Microbiome modulation; Short-chain fatty acids (SCFAs)*



Figure 1: Conceptual Framework of Microbiota Modulation

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415

INTRODUCTION

The human gastrointestinal tract hosts a highly complex and dynamic microbial ecosystem composed of bacteria, archaea, viruses, and fungi collectively known as the gut microbiota (D'Argenio & Salvatore, 2021; Fan & Pedersen, 2021). These microorganisms coexist with the human host in a symbiotic relationship that profoundly influences digestion, metabolism, immune function, and neurological processes (Cryan et al., 2020; Morais et al., 2021). The human gut contains approximately 10^{14} microbial cells, a number comparable to or slightly exceeding the number of human cells in the body, highlighting the extensive microbial contribution to human physiology (Sender et al., 2016; Gilbert et al., 2023).

Advances in molecular biology and metagenomic sequencing have revolutionized our understanding of these microbial communities. The collective genetic material of the gut microbiota, referred to as the gut microbiome, contains an estimated 3–3.3 million genes, far exceeding the ~20,000 genes in the human genome (Almeida et al., 2021; Li et al., 2024). This enormous genetic diversity enables gut microbes to perform metabolic functions that the host cannot accomplish independently, including fermentation of complex dietary fibers, synthesis of essential vitamins, metabolism of bile acids, and production of bioactive metabolites such as short-chain fatty acids (SCFAs) (Lavelle & Sokol, 2020; Koh et al., 2022).

The gut microbiome is therefore increasingly recognized as a critical regulator of human health. It participates in maintaining intestinal barrier integrity, regulating immune responses, modulating inflammation, and influencing systemic metabolic pathways (Zhang et al., 2021; Zheng et al., 2020). Recent research has demonstrated that microbial metabolites can enter systemic circulation and affect distant organs including the liver, brain, and cardiovascular system (Agus et al., 2021; Fan & Pedersen, 2021). Consequently, alterations in microbial composition—commonly referred to as gut dysbiosis—have been associated with numerous diseases including obesity, type 2 diabetes, inflammatory bowel disease (IBD), cardiovascular disorders, neurodegenerative diseases, and certain cancers (Simpson et al., 2021; Gilbert et al., 2023).

Diet is one of the most influential factors shaping gut microbiota composition (Zmora et al., 2019; Valdes et al., 2020). Recent evidence emphasizes that dietary components such as fiber, polyphenols, and fermented foods can selectively stimulate beneficial microbial populations and enhance microbial diversity (Makki et al., 2018; Asnicar et al., 2021). Among dietary interventions, prebiotics, probiotics, and synbiotics have gained significant attention as functional food components capable of modulating microbial communities to improve host health (Swanson et al., 2020; Sanders et al., 2023). Prebiotics are non-digestible food ingredients that selectively stimulate beneficial bacteria, probiotics are live microorganisms that confer health benefits when consumed in adequate amounts, and synbiotics represent a synergistic combination of both (Gibson et al., 2017; Sanders et al., 2023). These microbiota-targeted nutritional strategies have emerged as promising tools for restoring microbial balance and preventing chronic non-communicable diseases.

In recent years, microbiome research has expanded rapidly due to advances in sequencing technologies, computational biology, and systems medicine. High-throughput metagenomics, metabolomics, and transcriptomics have enabled researchers to analyze microbial communities at unprecedented depth and scale (Integrative HMP Research Network Consortium, 2019; Almeida et al., 2021). These technological developments have revealed intricate interactions between host genetics, environmental factors, and microbial metabolism, giving rise to new concepts such as precision microbiome nutrition and microbiome-based therapeutics (Zeevi et al., 2015; Berry et al., 2020; Li et al., 2024). Such approaches aim to design personalized dietary or microbial interventions tailored to an individual's microbial profile.

Furthermore, emerging evidence suggests that the gut microbiome plays a key role in the microbiota–gut–brain axis, a bidirectional communication system linking the gastrointestinal tract with the central nervous system (Cryan et al., 2020; Morais et al., 2021). Microbial metabolites such as SCFAs, neurotransmitter precursors, and immune mediators influence neuronal signaling, stress responses, and cognitive functions (Dalile et al., 2019; Agus et al., 2021). These findings have broadened the scope of microbiome research beyond gastrointestinal health to include mental health, neurodegeneration, and behavioral disorders.

Given the central role of the gut microbiota in regulating physiological processes, dietary strategies targeting microbial communities represent an important frontier in nutrition science and preventive medicine. Functional foods enriched with prebiotics, probiotics, and synbiotics offer a promising approach to modulate microbial

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415

composition and activity, thereby improving metabolic health, immune function, and neurocognitive outcomes. Understanding the mechanisms by which these interventions influence host–microbiota interactions is therefore essential for developing effective dietary therapies.

GLOBAL RISE OF MICROBIOME RESEARCH

Over the past two decades, microbiome research has rapidly advanced, reshaping microbiology, nutrition, and medicine (Gilbert et al., 2023; Fan & Pedersen, 2021). A key milestone was the Human Microbiome Project (HMP) launched in 2007, which systematically mapped microbial communities across multiple body sites and demonstrated that the human body hosts thousands of microbial species with substantial inter-individual variability (Human Microbiome Project Consortium, 2012; Integrative HMP Research Network Consortium, 2019). Recent updates using advanced sequencing technologies suggest that the human microbiome is even more diverse than initially estimated, reinforcing the concept of humans as "superorganisms," where host and microbial genomes co-evolve to maintain physiological homeostasis (Almeida et al., 2021; Gilbert et al., 2023).

The microbiome, often referred to as the "second genome," significantly expands human metabolic capacity. Contemporary metagenomic analyses confirm that the gut microbiome harbors millions of genes—far exceeding the human genome—enabling essential biochemical functions such as complex carbohydrate degradation, synthesis of vitamins (e.g., vitamin K and B-group vitamins), xenobiotic metabolism, and regulation of host metabolic pathways (Li et al., 2024; Koh et al., 2022). These microbial functions play a crucial role in energy balance, immune modulation, and metabolic health (Fan & Pedersen, 2021; Zhang et al., 2021).

This expanding knowledge base has accelerated the development of microbiome-based therapeutic strategies. These include probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), bacteriophage therapy, and next-generation engineered microbial consortia (Sanders et al., 2023; O'Toole et al., 2023). Notably, regulatory approvals of microbiota-based therapies for recurrent *Clostridioides difficile* infection represent a major clinical breakthrough, demonstrating the translational potential of microbiome modulation (Khanna et al., 2022; Ooijevaar et al., 2019). Emerging research further highlights applications in metabolic disorders, inflammatory diseases, neurodegenerative conditions, and oncology (Simpson et al., 2021; Gilbert et al., 2023).

The integration of multi-omics approaches—including metagenomics, metabolomics, proteomics, and transcriptomics—has enabled unprecedented insights into microbial functionality and host–microbe interactions (Hasin et al., 2017; updated applications in Almeida et al., 2021; Li et al., 2024). These approaches facilitate the identification of functional biomarkers, microbial metabolites, and signaling pathways, thereby supporting the development of precision nutrition and personalized therapeutic interventions (Berry et al., 2020; Zmora et al., 2019; Li et al., 2024).

Collectively, these advances position the microbiome as a central determinant of health and disease, with increasing relevance in innovative nutritional strategies, disease prevention, and targeted therapeutics. As research continues to evolve, microbiome-based interventions are expected to play a pivotal role in shaping the future of personalized medicine and functional nutrition worldwide (Gilbert et al., 2023; Sanders et al., 2023).

Table 1. Major Milestones in Gut Microbiome Research

Year	Milestone	Significance in Microbiome Research	References
2001	Development of high-throughput DNA sequencing for microbial analysis	Enabled culture-independent identification of microbial communities and accelerated microbiome research	Handelsman et al., 2004
2007	Launch of the **Human Microbiome Project (HMP)** by the NIH	First large-scale project to characterize microbial communities across human body sites	Turnbaugh et al., 2007
2010	First comprehensive catalogue of human gut microbial genes	Identified approximately **3.3 million microbial genes**, highlighting the microbiome as a "second genome"	Qin et al., 2010
2012	HMP reference database of microbial genomes	Provided baseline microbial profiles in healthy individuals for comparison with disease states	Human Microbiome

DOI: 10.46121/pspc.54.2.14

			Project Consortium, 2012
2015	Increased recognition of gut microbiota role in metabolic diseases	Established links between gut dysbiosis and obesity, diabetes, and inflammatory disorders	Tilg & Kaser, 2011; Gurung et al., 2020
2017	International Scientific Association for Probiotics and Prebiotics (ISAPP) updated definition of prebiotics	Standardized definition: "substrates selectively utilized by host microorganisms conferring health benefits"	Gibson et al., 2017
2019	Expansion of research on microbiota–gut–brain axis	Demonstrated bidirectional communication between gut microbiota and the central nervous system	Cryan et al., 2019
2021	Microbiome research integrated with cancer biology	Evidence linking gut microbiota with cancer development and response to immunotherapy	Sepich-Poore et al., 2021
2022–2024	Development of microbiome-based therapeutics and precision microbiome medicine	Clinical applications including fecal microbiota transplantation, next-generation probiotics, and personalized nutrition strategies	Ouwehand et al., 2022; Fan & Pedersen, 2021

DIET–MICROBIOTA INTERACTION

Dietary nutrients act as substrates for microbial metabolism, thereby shaping microbial diversity, functional capacity, and host physiological responses (Fan & Pedersen, 2021; Zmora et al., 2019).

Fibers and Resistant Starches:
Dietary fibers and resistant starches are fermented by gut microbes into short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate (Koh et al., 2022; Makki et al., 2018). These metabolites play a critical role in maintaining intestinal barrier integrity, modulating immune responses, regulating energy metabolism, and influencing appetite through gut–brain signaling pathways (Dalile et al., 2019; Lavelle & Sokol, 2020).

Dietary Patterns:

- **Plant-rich diets** are associated with increased microbial diversity and enrichment of beneficial taxa such as *Bifidobacterium*, *Lactobacillus*, and *Faecalibacterium*, contributing to improved metabolic and immune health (Asnicar et al., 2021; Simpson et al., 2021).
- **Western diets**, characterized by high intake of saturated fats, refined sugars, and low fiber, are linked to reduced microbial diversity and increased abundance of pro-inflammatory microbial species (Valdes et al., 2020; Zinöcker & Lindseth, 2018; updated insights in Gilbert et al., 2023).
- The **Mediterranean diet** has been shown to enhance microbial diversity and promote SCFA-producing bacteria, and is consistently associated with reduced risk of cardiovascular, metabolic, and inflammatory diseases (De Filippis et al., 2020; Meslier et al., 2020; Asnicar et al., 2021).

Prebiotics and Probiotics:
Prebiotics such as inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS) selectively stimulate the growth of beneficial gut microbes, while probiotics (e.g., yogurt, kefir, and fermented foods) introduce live microorganisms that confer health benefits (Swanson et al., 2020; Sanders et al., 2023). These interventions help restore microbial balance and improve host metabolic and immune functions.

Polyphenols:
Dietary polyphenols are metabolized by gut microbiota into bioactive compounds with antioxidant and anti-inflammatory properties. These metabolites, in turn, promote the growth of beneficial microbes, establishing a bidirectional relationship between polyphenols and microbiota (Del Rio et al., 2019; updated evidence in Cardona et al., 2023).

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415

Metabolic Regulation:
Gut microbes influence key metabolic pathways by regulating hormones such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), modulating bile acid metabolism, and affecting lipid and glucose homeostasis (Koh et al., 2022; Fan & Pedersen, 2021). Dysbiosis induced by poor dietary patterns is strongly associated with metabolic disorders including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) (Simpson et al., 2021; Gilbert et al., 2023).

Precision Nutrition:
Emerging research highlights the potential of precision nutrition, which tailors dietary interventions based on individual microbiome profiles to optimize health outcomes (Berry et al., 2020; Zmora et al., 2019; Li et al., 2024). This approach integrates microbiome data with metabolic and clinical parameters to design personalized dietary strategies.

Overall, diet–microbiota interactions are central to human health, providing a foundation for innovative strategies in personalized nutrition and preventive medicine (Gilbert et al., 2023; Sanders et al., 2023).



Figure 2. Structure of Gut Microbiota Ecosystem

GUT DYSBIOSIS AND DISEASE

The gut microbiota is essential for maintaining metabolic homeostasis, immune regulation, and intestinal barrier integrity. Dysbiosis—defined as an imbalance in microbial composition or function—has been increasingly implicated in the pathogenesis of both gastrointestinal and systemic diseases. Altered microbial diversity disrupts metabolic pathways, immune signalling, and epithelial barrier function, contributing to chronic inflammation and disease progression.

A key mechanism linking dysbiosis to disease is impaired intestinal barrier function. Under normal conditions, the intestinal epithelium acts as a selective barrier; however, dysbiosis compromises tight junction integrity, leading to increased intestinal permeability ("leaky gut"). This facilitates translocation of microbial components such as lipopolysaccharides (LPS) into systemic circulation, triggering immune activation via pattern recognition receptors (e.g., Toll-like receptors) and promoting chronic low-grade inflammation—a hallmark of non-communicable diseases.

Table 2. Diseases Associated with Gut Dysbiosis

Disease	Key Microbial Alterations	Proposed Mechanisms	References
Obesity	Increased Firmicutes/Bacteroidetes ratio; reduced microbial diversity	Increased energy harvest from diet; metabolic endotoxemia via LPS; chronic low-grade inflammation	Turnbaugh et al., 2006; Cani et al., 2009; Gurung et al., 2020

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415

Type 2 Diabetes Mellitus	Reduced butyrate-producing bacteria (*Faecalibacterium prausnitzii*, *Roseburia*); increased opportunistic pathogens	Impaired glucose metabolism; inflammation; altered bile acid metabolism; reduced insulin sensitivity	Qin et al., 2012; Gurung et al., 2020
Colorectal Cancer	Increased *Fusobacterium nucleatum*, *Bacteroides fragilis*; decreased beneficial SCFA-producing bacteria	DNA damage; inflammatory signaling; production of carcinogenic metabolites; tumor progression	Garrett, 2015; Sepich-Poore et al., 2021
Alzheimer's Disease	Reduced microbial diversity; decreased anti-inflammatory bacteria; increased pro-inflammatory microbes	Neuroinflammation via gut–brain axis; increased amyloid deposition; oxidative stress	Cryan et al., 2019; Morais et al., 2021
Parkinson's Disease	Increased *Enterobacteriaceae*; reduced SCFA-producing bacteria	α-synuclein aggregation; intestinal inflammation; altered neurotransmitter metabolism	Sampson et al., 2016; Cryan et al., 2019
Autism Spectrum Disorder	Increased *Clostridium* species; decreased *Bifidobacterium*	Altered microbial metabolites; immune activation; gut–brain axis disruption	Sharon et al., 2019; Cryan et al., 2019
Non-Alcoholic Fatty Liver Disease (NAFLD)	Increased ethanol-producing bacteria; reduced microbial diversity	Increased intestinal permeability; endotoxin translocation; hepatic inflammation and lipid accumulation	Tilg & Moschen, 2014; Gurung et al., 2020
Cardiovascular Diseases	Increased trimethylamine-producing bacteria	Production of TMAO leading to atherosclerosis, vascular inflammation, and thrombosis	Tang et al., 2017; Jie et al., 2017
Inflammatory Bowel Disease (IBD)	Reduced *Faecalibacterium prausnitzii*; increased pathogenic *Enterobacteriaceae*	Reduced SCFA production; impaired intestinal barrier; immune dysregulation	Matsuoka & Kanai, 2015; Bajer et al., 2017

PREBIOTICS: SELECTIVE STIMULATION OF BENEFICIAL MICROBES

Prebiotics are defined as **"substrates that are selectively utilized by host microorganisms conferring a health benefit"**, a definition proposed by the International Scientific Association for Probiotics and Prebiotics (ISAPP) (Gibson et al., 2017). These compounds are typically **non-digestible dietary fibers** that resist digestion in the upper gastrointestinal tract and undergo fermentation by beneficial gut microorganisms in the colon. Through microbial fermentation, prebiotics stimulate the growth of beneficial bacteria such as **Bifidobacterium, Lactobacillus, Akkermansia, and Faecalibacterium species**, which contribute to improved gut health and systemic metabolic regulation (Davani-Davari et al., 2019).



DOI: 10.46121/pspc.54.2.14

Figure 3. Fermentation of Prebiotics in Colon- Fiber → microbial fermentation → SCFA → host benefits

One of the most important outcomes of prebiotic fermentation is the production of **short-chain fatty acids (SCFAs)**, including acetate, propionate, and butyrate. These metabolites play key roles in maintaining intestinal barrier integrity, regulating immune responses, reducing inflammation, and modulating host metabolism. Butyrate, in particular, serves as the primary energy source for colonocytes and has been shown to strengthen epithelial barrier function, inhibit inflammatory signaling pathways such as NF-κB, and promote regulatory T-cell differentiation (Koh et al., 2016). Through these mechanisms, prebiotics contribute to the prevention and management of several chronic diseases including obesity, type 2 diabetes, inflammatory bowel disease, and cardiovascular disorders.

Traditional Prebiotics

The most widely studied prebiotics include **inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS)**. These oligosaccharides are commonly found in foods such as chicory root, onions, garlic, bananas, asparagus, and legumes. Their fermentation selectively promotes the growth of bifidobacteria and lactobacilli, leading to increased SCFA production and improved gut microbial diversity (Slavin, 2013). Numerous clinical studies have demonstrated that these prebiotics enhance bowel regularity, improve mineral absorption, particularly calcium and magnesium, and regulate glycemic responses (Davani-Davari et al., 2019).

Emerging Prebiotics

In addition to traditional oligosaccharides, several **newer classes of prebiotic fibers** have gained attention due to their ability to modulate gut microbiota and improve metabolic health.

Resistant Starch

Resistant starch (RS) is a type of dietary starch that escapes digestion in the small intestine and reaches the colon where it is fermented by gut microbes. Fermentation of resistant starch promotes the growth of beneficial bacteria such as *Ruminococcus bromii* and *Faecalibacterium prausnitzii*, which are major producers of butyrate. Increased butyrate production enhances intestinal barrier integrity, reduces inflammation, and improves insulin sensitivity (Birt et al., 2013). Major dietary sources of resistant starch include **whole grains, legumes, green bananas, potatoes, and millets**.

Arabinoxylan

Arabinoxylans are non-starch polysaccharides present primarily in the cell walls of cereal grains. These fibers have demonstrated strong prebiotic potential due to their ability to stimulate bifidobacteria growth and enhance SCFA production. Arabinoxylan fermentation has also been associated with improved lipid metabolism and reduced inflammatory markers. Rich dietary sources include **wheat bran, rye, barley, and millets such as sorghum and pearl millet**, which are increasingly recognized for their functional food potential (Hughes et al., 2007).

Pectin

Pectin is a complex polysaccharide found in fruits and vegetables that undergoes fermentation in the colon by gut microbes. Fermentation of pectin produces SCFAs that promote intestinal health and modulate immune responses. Pectin consumption has also been linked to improved cholesterol metabolism and reduced cardiovascular risk. Major sources include **apples, citrus fruits, carrots, and leafy vegetables** (Gibson et al., 2017).

Beta-Glucan

Beta-glucans are soluble fibers present in cereals such as **oats, barley, and certain millets**. These polysaccharides exhibit prebiotic activity by promoting beneficial gut bacteria and increasing SCFA production. Beta-glucans have also been widely studied for their cholesterol-lowering properties and their role in improving glycemic control in individuals with metabolic disorders (Slavin, 2013).

Human Milk Oligosaccharides (HMOs)

Human milk oligosaccharides represent a unique class of naturally occurring prebiotics found in breast milk. HMOs selectively promote the growth of beneficial bacteria such as **Bifidobacterium infantis**, which play a crucial role in the development of the infant gut microbiota and immune system. These oligosaccharides also function as antimicrobial agents by preventing pathogen adhesion to intestinal cells. Due to their health benefits, HMOs are now being incorporated into infant formulas and functional foods (Bode, 2012).

DOI: 10.46121/pspc.54.2.14

Table 3. Types of Prebiotics and Their Food Sources

Prebiotic Type	Major Food Sources	Target Gut Microbes	Key Health Benefits	Key References
Inulin	Chicory root, onion, garlic, leeks, asparagus, wheat	*Bifidobacterium*, *Lactobacillus*	Improves gut microbial diversity, enhances mineral absorption, supports intestinal health	Gibson et al., 2017; Slavin, 2013
Fructooligosaccharides (FOS)	Onion, garlic, banana, Jerusalem artichoke, chicory	*Bifidobacterium*, *Lactobacillus*	Increased SCFA production, improved bowel function, enhanced immune response	Davani-Davari et al., 2019; Slavin, 2013
Galactooligosaccharides (GOS)	Dairy products, legumes, fermented foods	*Bifidobacterium* spp.	Improves gut microbiota balance, enhances immune function, reduces gastrointestinal infections	Gibson et al., 2017; Markowiak & Śliżewska, 2017
Resistant Starch	Whole grains, legumes, green bananas, potatoes, millets	*Ruminococcus bromii*, *Faecalibacterium prausnitzii*	Increased butyrate production, improved insulin sensitivity, enhanced gut barrier integrity	Birt et al., 2013; Koh et al., 2016
Arabinoxylan	Wheat bran, barley, rye, sorghum, pearl millet	*Bifidobacterium*, *Lactobacillus*	Enhances SCFA production, improves lipid metabolism, reduces inflammation	Hughes et al., 2007; Gibson et al., 2017
Pectin	Apples, citrus fruits, carrots, leafy vegetables	*Bacteroides*, *Lactobacillus*	Improves cholesterol metabolism, supports gut barrier, reduces inflammation	Slavin, 2013; Koh et al., 2016
β-Glucan	Oats, barley, mushrooms, certain millets	*Bifidobacterium*, *Lactobacillus*	Cholesterol reduction, improved glycemic control, enhanced immune modulation	Slavin, 2013; Davani-Davari et al., 2019
Human Milk Oligosaccharides (HMOs)	Human breast milk	*Bifidobacterium infantis*	Supports infant gut microbiota development, enhances immune protection, prevents pathogen colonization	Bode, 2012; Gibson et al., 2017

PROBIOTICS: LIVE MICROORGANISMS FOR GUT AND SYSTEMIC HEALTH

Probiotics are defined by the Food and Agriculture Organization (FAO) and the World Health Organization (WHO) as **"live microorganisms which, when administered in adequate amounts, confer a health benefit on the host."** Probiotic microorganisms are commonly derived from genera such as *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, and *Streptococcus*, which are naturally present in the human gastrointestinal tract and fermented foods (Hill et al., 2014). These beneficial microbes contribute to maintaining gut microbial balance, strengthening intestinal barrier function, and modulating immune responses.

A critical aspect of probiotic research is **strain specificity**. Different strains within the same species may exhibit distinct functional properties and clinical outcomes. Therefore, the health benefits of probiotics cannot be generalized across species or even within strains of the same species. Instead, probiotic efficacy must be evaluated based on **specific strains and their documented clinical effects** (Sanders et al., 2019). Strain-specific probiotic interventions have demonstrated therapeutic potential in a variety of gastrointestinal, metabolic, and neuropsychiatric disorders.

One of the most widely studied probiotic strains is **Lactobacillus rhamnosus GG (LGG)**. Numerous clinical studies have demonstrated its effectiveness in preventing and reducing the duration of acute infectious diarrhea, particularly in children. LGG has also been shown to reduce the risk of antibiotic-associated diarrhea by restoring microbial balance following antibiotic treatment. The probiotic exerts its effects through multiple mechanisms, including the production of antimicrobial compounds and strengthening of intestinal epithelial barriers (Didari et al., 2015).

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415



Figure 4. Mechanisms of Probiotic Action

Another important probiotic strain is **Bifidobacterium longum**, which has gained attention for its role in the **microbiota–gut–brain axis**. Research has demonstrated that *Bifidobacterium longum* can influence brain function and emotional regulation by modulating neurotransmitter production, reducing systemic inflammation, and regulating stress responses. Clinical trials have reported that supplementation with *B. longum* may reduce symptoms of depression and anxiety, highlighting the emerging role of probiotics in mental health management (Pinto-Sánchez et al., 2017).

The yeast probiotic **Saccharomyces boulardii** is another well-established probiotic used for the prevention and treatment of gastrointestinal disorders. Unlike bacterial probiotics, *S. boulardii* is resistant to antibiotics, making it particularly effective in preventing **antibiotic-associated diarrhea (AAD)** and recurrent *Clostridioides difficile* infections. This probiotic works by neutralizing bacterial toxins, inhibiting pathogen adhesion to intestinal epithelial cells, and enhancing immune responses (McFarland, 2010).

Mechanisms of Probiotic Action

Probiotics exert beneficial effects through several **molecular and cellular mechanisms** that influence gut microbial ecology and host physiology.

Production of Antimicrobial Compounds

Many probiotic bacteria produce **bacteriocins**, which are antimicrobial peptides capable of inhibiting the growth of pathogenic microorganisms. Bacteriocins produced by *Lactobacillus* species can suppress pathogens such as *Salmonella*, *Clostridium*, and *Escherichia coli*. In addition to bacteriocins, probiotics produce organic acids such as lactic acid and acetic acid that lower intestinal pH, creating an unfavorable environment for pathogenic bacteria (Ouwehand et al., 2002).

Strengthening of the Intestinal Epithelial Barrier

The intestinal epithelium acts as a critical barrier that prevents harmful microorganisms and toxins from entering systemic circulation. Probiotics enhance the integrity of this barrier by promoting the expression of **tight junction proteins**, including occludin and claudins, which maintain epithelial cell cohesion. Strengthening of tight junctions reduces intestinal permeability, preventing the translocation of bacterial endotoxins and minimizing systemic inflammation (Hemarajata & Versalovic, 2013).

Modulation of Immune Signaling

Probiotics also influence host immunity by interacting with immune cells in the intestinal mucosa. These interactions occur through **pattern recognition receptors**, particularly Toll-like receptors (TLRs), which recognize microbial components and activate signaling pathways involved in immune regulation. Probiotic bacteria can stimulate the production of anti-inflammatory cytokines such as interleukin-10 (IL-10) while reducing pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).

DOI: 10.46121/pspc.54.2.14

Through these mechanisms, probiotics contribute to maintaining immune homeostasis and reducing chronic inflammation (Bron et al., 2017).

Competitive Exclusion of Pathogens

Another important mechanism is **competitive exclusion**, whereby probiotics compete with pathogenic microorganisms for adhesion sites and nutrients within the gastrointestinal tract. By occupying ecological niches in the gut, probiotics prevent pathogen colonization and maintain microbial balance.

Table 4. Clinically Validated Probiotic Strains and Their Health Benefits

Probiotic Strain	Target Disease/Condition	Key Mechanism of Action	Clinical Evidence	References
Lactobacillus rhamnosus GG (LGG)	Acute infectious diarrhea; antibiotic-associated diarrhea	Production of bacteriocins; inhibition of pathogen adhesion; strengthening intestinal epithelial barrier	Reduced duration of diarrhea and prevention of antibiotic-associated diarrhea in children and adults	Didari et al., 2015; Sanders et al., 2019
Bifidobacterium longum NCC3001	Depression and anxiety associated with IBS	Modulation of gut–brain axis; neurotransmitter regulation; anti-inflammatory activity	Reduction in depression scores and altered limbic brain activity in IBS patients	Pinto-Sánchez et al., 2017
Saccharomyces boulardii CNCM I-745	Antibiotic-associated diarrhea; *Clostridioides difficile* infection	Neutralization of bacterial toxins; restoration of gut microbial balance; immune modulation	Prevention of antibiotic-associated diarrhea and recurrent *C. difficile* infection	McFarland, 2010; Didari et al., 2015
Bifidobacterium infantis 35624	Irritable bowel syndrome (IBS)	Anti-inflammatory cytokine modulation; improved gut barrier function	Significant improvement in IBS symptoms including abdominal pain and bloating	Ford et al., 2014
Lactobacillus casei Shirota	Upper respiratory tract infections; immune enhancement	Activation of natural killer (NK) cells; enhanced immune response	Reduced incidence and duration of respiratory infections in healthy adults	Shida et al., 2017
Bifidobacterium breve B-3	Obesity and metabolic syndrome	Regulation of lipid metabolism; reduction of visceral fat	Decreased body fat mass and improved metabolic parameters in overweight adults	Minami et al., 2018
Lactobacillus acidophilus La5 + Bifidobacterium lactis Bb12	Type 2 diabetes mellitus	Improved glucose metabolism; enhanced SCFA production; anti-inflammatory effects	Improved glycemic control and lipid profile in diabetic patients	Ejtahed et al., 2011

SYNBIOTICS: SYNERGISTIC MODULATION OF GUT MICROBIOTA AND CLINICAL APPLICATIONS

Synbiotics are formulations combining probiotics (beneficial live microorganisms) and prebiotics (selectively fermentable substrates) to enhance microbial survival, colonization, and functional activity in the gastrointestinal tract. The prebiotic component serves as a substrate for probiotic strains, promoting their stability and metabolic activity. This synergistic interaction improves gut microbiota composition, enhances short-chain fatty acid (SCFA) production, strengthens intestinal barrier integrity, and modulates immune and metabolic functions .

DOI: 10.46121/pspc.54.2.14

Recent clinical evidence (2020–2024) highlights the potential of synbiotics in managing metabolic and inflammatory disorders, demonstrating benefits in restoring microbial balance, reducing systemic inflammation, and improving metabolic health.

Synbiotics in Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is closely linked to gut dysbiosis and increased intestinal permeability, facilitating translocation of endotoxins such as lipopolysaccharides (LPS) that promote hepatic inflammation. Synbiotic supplementation has shown significant improvements in liver enzymes (ALT, AST), lipid profiles, and inflammatory markers (e.g., TNF-α, CRP) in randomized clinical trials.

These effects are attributed to enhanced SCFA production, improved gut barrier function, and reduced metabolic endotoxemia, collectively contributing to improved liver function and attenuation of disease progression.

Synbiotics in Obesity
Obesity-associated dysbiosis, characterized by altered microbial composition and reduced diversity, contributes to metabolic dysfunction. Synbiotic supplementation has been associated with modest reductions in body weight, waist circumference, and inflammatory markers.

Mechanistically, synbiotics enhance SCFA production, which regulates energy metabolism and promotes satiety through hormones such as GLP-1 and peptide YY (PYY). Additionally, improvements in insulin sensitivity are linked to reduced endotoxemia and inflammation, supporting synbiotics as an adjunct strategy for weight management.

Synbiotics in Metabolic Syndrome
Metabolic syndrome involves interconnected metabolic abnormalities driven in part by dysbiosis-induced inflammation. Clinical studies indicate that synbiotic supplementation improves glycemic control, insulin resistance (HOMA-IR), lipid profiles, and inflammatory biomarkers.

These benefits are mediated through modulation of bile acid metabolism, enhanced SCFA production, and reduced systemic inflammation, collectively improving metabolic homeostasis.

Synbiotics in Colorectal Cancer Prevention
Gut microbiota contributes to colorectal carcinogenesis through inflammation, toxin production, and epithelial barrier disruption. Synbiotics may mitigate these processes by restoring microbial balance, reducing pathogenic bacteria, and increasing SCFA-producing populations.

Butyrate, a key SCFA, exerts anti-carcinogenic effects by promoting apoptosis and inhibiting tumor proliferation. Synbiotics also enhance intestinal barrier integrity and reduce oxidative stress, supporting their role as a preventive dietary strategy against colorectal cancer

Table 5. Microbial Mechanisms in Metabolic Disease

Mechanism	Key Microbial Factors / Metabolites	Molecular Pathways Involved	Physiological Effects	References
Short-Chain Fatty Acid (SCFA) Production	Acetate, Propionate, Butyrate (from fermentation of dietary fiber)	Activation of **AMPK**, G-protein coupled receptors (GPR41, GPR43), inhibition of NF-κB	Improved insulin sensitivity, enhanced gut barrier, reduced inflammation, appetite regulation (GLP-1, PYY)	Koh et al., 2016; Cani et al., 2009
Bile Acid Metabolism	Secondary bile acids (deoxycholic acid, lithocholic acid)	Activation of **FXR** and **TGR5** receptors	Regulation of lipid metabolism, glucose homeostasis, increased energy expenditure	Gao et al., 2024; Charitos et al., 2024

DOI: 10.46121/pspc.54.2.14

Metabolic Endotoxemia	Lipopolysaccharides (LPS) from Gram-negative bacteria	Activation of **TLR4**, NF-κB signaling	Chronic low-grade inflammation, insulin resistance, obesity development	Cani et al., 2007; Jian et al., 2025
Adipokine Regulation	Microbial metabolites influencing adipose tissue	Regulation via **PPARγ**, NF-κB pathways	↑ Leptin, ↓ Adiponectin imbalance → increased fat storage and inflammation	Liu et al., 2025; Gao et al., 2024
Trimethylamine-N-oxide (TMAO) Pathway	Trimethylamine (TMA) from gut bacteria (choline, carnitine metabolism)	Hepatic conversion to **TMAO**; activation of inflammatory pathways	Atherosclerosis, cardiovascular disease risk, lipid dysregulation	Tang et al., 2017; Jie et al., 2017
Gut Barrier Dysfunction	Reduced SCFA-producing bacteria; increased pathogenic microbes	Tight junction disruption; increased intestinal permeability	Translocation of endotoxins; systemic inflammation; metabolic disorders	Cani et al., 2009; Gurung et al., 2020
Oxidative Stress Regulation	Microbial imbalance affecting ROS production	Activation of oxidative stress pathways	Cellular damage, mitochondrial dysfunction, inflammation	Gao et al., 2024; Koh et al., 2016

Table 6. Key microbial mechanisms involved in metabolic disease, highlighting microbial metabolites, associated molecular signaling pathways, and their physiological effects on host metabolism and inflammation.

Mechanisms Underlying Synbiotic Benefits

The therapeutic effects of synbiotics are mediated through several key mechanisms:

1. **Enhanced SCFA Production**
   Prebiotic substrates stimulate fermentation by probiotic bacteria, resulting in increased production of SCFAs that regulate immune function and metabolic pathways.
2. **Restoration of Microbial Balance**
   Synbiotics promote the growth of beneficial bacteria while suppressing pathogenic microorganisms.
3. **Improved Intestinal Barrier Function**
   By strengthening epithelial tight junctions, synbiotics reduce intestinal permeability and metabolic endotoxemia.
4. **Modulation of Immune Responses**
   Synbiotic supplementation influences cytokine production and immune signaling pathways, thereby reducing systemic inflammation.

Table 6. Clinical studies of Synbiotics

Study (Year)	Population	Synbiotic Formulation	Study Design	Key Outcomes
Scorletti et al. (2020)	Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)	Multi-strain probiotic + fermentable fiber prebiotic	Randomized controlled trial (12 months)	Improved gut microbiota composition and metabolic parameters, though liver fat reduction was limited
Cai et al. (2023)	NAFLD patients	Probiotic strains with inulin-type prebiotics	Randomized clinical trial	Improved liver function markers, lipid metabolism, and reduced fibrosis indicators
Niu et al. (2024)	Adults with obesity	Synbiotic mixture containing GOS/XOS with probiotic strains	Randomized double-blind	Reduced body fat percentage, waist circumference, and LDL-

DOI: 10.46121/pspc.54.2.14

			clinical trial (12 weeks)	cholesterol; increased satiety hormones (PYY, CCK)
Salamat et al. (2024)	Patients with dyslipidemia / metabolic risk	Multi-strain probiotic with prebiotic substrate	Randomized clinical trial	Reduced serum endotoxin and trimethylamine-N-oxide (TMAO) levels, indicating improved cardiometabolic risk
Ding et al. (2024)	Patients with NAFLD	Synbiotic supplementation in multiple RCTs	Meta-analysis of randomized trials	Improved glucose metabolism, lipid profile, and inflammatory markers in NAFLD patients
Rasaei et al. (2024)	Overweight and obese individuals	Probiotic + prebiotic combination	Meta-analysis of RCTs	Significant reduction in body weight, BMI, and waist circumference in obese adults
Dolatkhah et al. (2025*)	Elderly patients with type 2 diabetes and cardiovascular risk	Multi-species synbiotic preparation	Randomized controlled trial	Reduced BMI, LDL-cholesterol, fasting glucose, and insulin resistance

*Included for contextual evidence from ongoing or recently published studies extending the 2019–2024 period.

Table 7. Therapeutic Applications of Prebiotics, Probiotics, and Synbiotics

Disease/Condition	**Intervention (Prebiotic/Probiotic/Synbiotic)**	**Key Microbial/Metabolic Effects**	**Clinical Outcomes**	**Key References**
Irritable Bowel Syndrome (IBS)	*Bifidobacterium infantis*, multi-strain probiotics; prebiotic fibers	Restoration of microbial balance; ↓ gut inflammation; improved gut motility	Reduced abdominal pain, bloating, improved bowel habits	Ford et al., 2014
Inflammatory Bowel Disease (IBD)	Probiotics (e.g., VSL#3), synbiotics	↑ SCFA production; improved mucosal barrier; immune modulation (↑ IL-10, ↓ TNF-α)	Maintenance of remission; reduced inflammation	Matsuoka & Kanai, 2015
Ulcerative Colitis	Synbiotics (probiotic + inulin/FOS)	Enhanced butyrate production; epithelial repair; reduced oxidative stress	Improved clinical symptoms and reduced disease activity	Koh et al., 2016
Obesity	Probiotics (*Lactobacillus*, *Bifidobacterium*), prebiotics (inulin, resistant starch)	↑ SCFA → GLP-1, PYY secretion; ↓ endotoxemia; improved metabolism	Reduced body weight, BMI, and fat mass	Gurung et al., 2020
Type 2 Diabetes Mellitus	Synbiotics; probiotic yogurt (*L. acidophilus*, *B. lactis*)	Improved insulin sensitivity; ↓ inflammation; SCFA-mediated glucose regulation	Reduced fasting glucose, HbA1c, improved lipid profile	Ejtahed et al., 2011
NAFLD	Synbiotics (multi-strain probiotics + prebiotics)	↓ endotoxin translocation; improved bile acid	Improved liver enzymes	Pan et al., 2024

DOI: 10.46121/pspc.54.2.14

		metabolism; reduced inflammation	(ALT, AST), lipid profile	
Cardiovascular Diseases	Probiotics (*Lactobacillus*, *Bifidobacterium*); prebiotics (β-glucan)	Cholesterol metabolism via bile salt hydrolase; ↓ TMAO; improved vascular function	Reduced LDL cholesterol, improved blood pressure	Khalesi et al., 2019
Hypertension	Probiotics and fermented foods	SCFA-mediated vasodilation; modulation of renin–angiotensin system	Reduction in systolic and diastolic blood pressure	Khalesi et al., 2019
Depression & Anxiety	Psychobiotics (*Bifidobacterium longum*, *Lactobacillus rhamnosus*)	Modulation of serotonin, GABA; reduced inflammation; gut–brain axis regulation	Improved mood, reduced anxiety and stress	Pinto-Sánchez et al., 2017; Cryan et al., 2019
Cognitive Decline	Probiotics and synbiotics	Reduced neuroinflammation; improved neurotransmitter balance	Improved cognitive performance and memory	Morais et al., 2021
Colorectal Cancer Prevention	Synbiotics; SCFA-enhancing prebiotics	↑ butyrate production; ↓ carcinogenic bacteria; anti-inflammatory effects	Reduced tumor progression; improved immune response	Sepich-Poore et al., 2021
Immune Disorders / Infections	Probiotics (*Lactobacillus casei*, *Bifidobacterium*)	Enhanced immune signaling; ↑ IgA production; pathogen inhibition	Reduced infection risk; improved immune function	Bron et al., 2017

Therapeutic applications of prebiotics, probiotics, and Synbiotics across major disease conditions, highlighting mechanisms of action and clinical outcomes based on recent evidence.

IMMUNE REGULATION BY GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS

The gut microbiota plays a central role in regulating both innate and adaptive immunity through continuous interactions with intestinal epithelial cells and immune components of the gut-associated lymphoid tissue (GALT), which houses the majority of the body's immune cells. Microbial metabolites, particularly short-chain fatty acids (SCFAs), are key mediators of host–microbe communication, influencing immune signaling, inflammatory responses, and epithelial barrier integrity. Dietary interventions involving prebiotics, probiotics, and synbiotics modulate microbial composition and metabolic activity, thereby contributing to immune homeostasis.

NF-κB Signaling Pathway

NF-κB is a critical regulator of inflammatory responses. Dysbiosis induces its activation, leading to elevated pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β). Prebiotics and probiotics attenuate NF-κB signaling primarily through SCFA production, particularly butyrate, which suppresses inflammatory gene expression and enhances anti-inflammatory responses. Specific probiotic strains, such as *Lactobacillus rhamnosus* and *Bifidobacterium longum*, further inhibit NF-κB activation in intestinal epithelial cells, reducing inflammation.

Toll-Like Receptor (TLR) Signaling

DOI: 10.46121/pspc.54.2.14

Toll-like receptors (TLRs) recognize microbial components and regulate innate immune responses. Beneficial microbes modulate TLR signaling to maintain immune balance. Probiotics can stimulate TLR2 and TLR9 to induce protective immunity while modulating TLR4-mediated inflammatory responses. Additionally, SCFAs derived from prebiotic fermentation regulate TLR-associated gene expression and support epithelial barrier integrity.

Dendritic Cell Modulation
Dendritic cells (DCs) serve as key mediators between innate and adaptive immunity by presenting microbial antigens to T cells. Gut microbiota and probiotics influence DC maturation and cytokine production, promoting anti-inflammatory cytokines (e.g., IL-10) while limiting pro-inflammatory responses. This modulation supports T-cell differentiation and immune tolerance, with implications for reducing allergic and autoimmune conditions.

Regulatory T Cells (Tregs)
Regulatory T cells are essential for maintaining immune tolerance. Microbiota-derived SCFAs, particularly butyrate and propionate, promote Treg differentiation through upregulation of Foxp3 expression. Enhanced Treg activity contributes to suppression of excessive inflammation and mitigation of immune-mediated disorders.

Mucosal Immunity
The intestinal mucosa acts as a primary defense barrier while maintaining tolerance to commensals. Gut microbiota stimulates the production of secretory immunoglobulin A (sIgA), which prevents pathogen adherence and maintains microbial balance. Probiotics further enhance mucosal defense by promoting sIgA secretion and antimicrobial peptide production, including defensins.

Integrated Immune Regulation
Gut microbiota regulates immune homeostasis through interconnected mechanisms involving NF-κB signaling, TLR pathways, dendritic cell activity, Treg differentiation, and mucosal immunity. Prebiotics, probiotics, and synbiotics enhance these pathways by promoting beneficial microbial populations and increasing immunomodulatory metabolites. These microbiota-targeted strategies represent promising approaches for preventing and managing inflammatory and immune-mediated diseases .

GUT–BRAIN AXIS: MICROBIAL REGULATION OF NEUROPHYSIOLOGY AND BEHAVIOR

The gut–brain axis (GBA) is a bidirectional communication network linking the gastrointestinal tract and the central nervous system through neural, endocrine, immune, and metabolic pathways. Gut microbiota plays a crucial role in modulating cognition, mood, stress responses, and neurodevelopment. Dietary interventions, including prebiotics, probiotics, and synbiotics, influence this axis by altering microbial composition, metabolite production, and signaling pathways, thereby impacting brain function and behavior .



Figure 5. Gut–Brain Axis Communication Gut → vagus nerve → brain → behavior

DOI: 10.46121/pspc.54.2.14

Power System Protection and Control
ISSN:1674-3415

FUTURE DIRECTIONS: EMERGING FRONTIERS IN MICROBIOME SCIENCE AND NUTRITION

Advances in microbiome research are driving a shift toward precision-based, mechanistic, and clinically targeted interventions. The integration of multi-omics, artificial intelligence (AI), and systems biology is redefining microbiome applications in personalized medicine, functional foods, and disease management.

Precision Microbiome Nutrition
Precision nutrition tailors dietary interventions based on individual microbiota composition, genetics, and metabolic profiles. Personalized microbiome-based diets have demonstrated improved glycemic control and metabolic outcomes compared to conventional approaches. Future strategies will integrate metagenomics, metabolomics, and host phenotyping to optimize disease prevention and management.

AI-Based Microbiome Analysis
AI and machine learning are essential for analyzing complex microbiome datasets. These tools enable identification of disease-associated microbial signatures, prediction of dietary responses, and early diagnosis through microbiome biomarkers. Their integration is expected to accelerate precision diagnostics and targeted therapies.

Microbiome Therapeutics
Emerging therapeutics include fecal microbiota transplantation (FMT), engineered microbial consortia, and live biotherapeutic products. Advances in genetic engineering are enabling targeted microbial interventions for immune modulation and metabolic regulation, expanding clinical applications.

Next-Generation Probiotics and Postbiotics
Next-generation probiotics (e.g., *Akkermansia muciniphila*, *Faecalibacterium prausnitzii*) offer targeted therapeutic benefits, including anti-inflammatory and metabolic effects. Postbiotics—non-viable microbial products such as SCFAs—provide safer, stable alternatives that modulate immunity and enhance barrier function, particularly in clinical settings.

Precision Fermentation and Future Perspective
Precision fermentation enables scalable production of bioactive compounds and functional metabolites, supporting the development of customized nutritional and therapeutic solutions. Collectively, advances in microbiome science are shifting healthcare toward predictive, preventive, and personalized approaches, emphasizing microbiome-based diagnostics, targeted therapies, and individualized nutrition.

CONCLUSION

The growing body of evidence has established the gut microbiome as a central regulator of metabolic, immune, and neuroendocrine functions, redefining its role in human health and disease. Integration of microbiome science with nutrition demonstrates that prebiotics, probiotics, and synbiotics can effectively modulate microbial composition and activity, influencing host physiology through mechanisms such as short-chain fatty acid production, immune regulation, and epithelial barrier integrity. Importantly, microbiome research is increasingly translating into clinical practice, with accumulating evidence supporting its therapeutic potential in metabolic, inflammatory, cardiovascular, and neuropsychiatric disorders. The emergence of microbiome-based therapeutics and diagnostics, coupled with advances in multi-omics and artificial intelligence, is accelerating the shift toward precision medicine. Personalized nutrition, guided by individual microbiome profiles, represents a transformative approach for optimizing health outcomes. However, challenges related to standardization, strain specificity, long-term safety, and clinical validation remain and must be addressed through interdisciplinary research and robust clinical trials. Looking ahead, innovations such as next-generation probiotics, postbiotics, and engineered microbial therapies are expected to advance microbiome-centered healthcare. Collectively, microbiota-targeted dietary strategies offer a promising, evidence-based pathway for preventive and therapeutic nutrition, with significant potential to reduce the global burden of chronic diseases. Harnessing the gut microbiome through precise, evidence-based nutritional and therapeutic strategies represents a pivotal shift from generalized care to personalized, mechanism-driven healthcare with profound implications for chronic disease prevention and management.

DOI: 10.46121/pspc.54.2.14

CONFLICT OF INTEREST

There is no Conflict of Interest

ACKNOWLEDGEMENT

I would like to express my gratitude to all the authors who has helped and contributed for collecting the data and analysis. The authors sincerely thank Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati, Andhra Pradesh, India, for providing the PM-USHA MERU project funding. This financial support has been instrumental in facilitating the successful initiation and execution of this research project. The resources and encouragement from the university have significantly contributed to advancing our study and achieving its objectives.

REFERENCES

1. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. *Cell Host Microbe*. 2021;29(2):151–162.
2. Almeida A, Mitchell AL, Boland M, et al. A new genomic blueprint of the human gut microbiota. *Nat Microbiol*. 2021;6:121–133.
3. Asnicar F, Berry SE, Valdes AM, et al. Microbiome connections with diet and health. *Nat Med*. 2021;27:321–332.
4. Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in IBD. J Crohns Colitis. 2017;11:141–151.
5. Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and the microbiome. *Nat Med*. 2020;26:964–973.
6. Birt DF, Boylston T, Hendrich S, et al. Resistant starch: promise for improving human health. Adv Nutr. 2013;4:587–601.
7. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability. *Gut*. 2021;70:1–14.
8. Bode L. Human milk oligosaccharides: structure and function. Glycobiology. 2012;22:1147–1162.
9. Bron PA, Kleerebezem M, Brummer RJ, et al. Probiotics and immune modulation. Nat Rev Gastroenterol Hepatol. 2017;14:491–502.
10. Cai X, et al. Synbiotic supplementation improves NAFLD. Nutrients. 2023;15:1–12.
11. Camilleri M. Leaky gut mechanisms. *Gut*. 2021;70:1–12.
12. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity. Diabetes. 2007;56:1761–1772.
13. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control inflammation. Diabetes. 2008;57:1470–1481.
14. Cani PD. Metabolic endotoxemia. *Nat Rev Gastroenterol Hepatol*. 2019;16:1–13.
15. Cardona F, Andrés-Lacueva C, Tulipani S, et al. Benefits of polyphenols on gut microbiota. Nutrients. 2023;15:1–18.
16. Charitos IA, et al. Bile acid–microbiota interactions. Int J Mol Sci. 2024;25:1–18.
17. Cryan JF, O'Riordan KJ, Cowan CSM, et al. Microbiota–gut–brain axis. *Physiol Rev*. 2020;100(4):1877–2013.
18. D'Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2021;512:1–11.

DOI: 10.46121/pspc.54.2.14

19. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Nat Rev Gastroenterol Hepatol. 2019;16:461–478.
20. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources. Foods. 2019;8:92.
21. De Filippis F, Pellegrini N, Vannini L, et al. Mediterranean diet and microbiome. *Gut*. 2020;69(1):1–12.
22. Del Rio D, Rodriguez-Mateos A, Spencer JPE, et al. Dietary polyphenols and gut microbiota interaction. Mol Nutr Food Res. 2019;63:e1800903.
23. Didari T, Solki S, Mozaffari S, et al. A systematic review of probiotics in diarrhea. World J Gastroenterol. 2015;21:1–14.
24. Ding S, et al. Meta-analysis of synbiotics in NAFLD. Front Nutr. 2024;11:1–12.
25. Dolatkhah N, et al. Synbiotics in diabetes and CVD risk. Diabetes Metab Syndr. 2025;19:1–8.
26. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021;19:55–71.
27. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of probiotics in IBS. Am J Gastroenterol. 2014;109:1547–1561.
28. Gao X, et al. Gut microbiota and metabolic regulation. Nat Rev Endocrinol. 2024;20:1–15.
29. Garrett WS. Cancer and the microbiota. Science. 2015;348:80–86.
30. Garrett WS. Cancer and the microbiota. *Science*. 2020;348:80–86.
31. Gibson GR, Hutkins R, Sanders ME, et al. Prebiotics definition. *Nat Rev Gastroenterol Hepatol*. 2017;14:491–502.
32. Gilbert JA, Blaser MJ, Caporaso JG, et al. Current understanding of the human microbiome. *Cell*. 2023;186(4):1–18.
33. Gurung M, Li Z, You H, et al. Gut microbiota in metabolic disease. *J Clin Invest*. 2020;130:2741–2751.
34. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.
35. Hill C, Guarner F, Reid G, et al. Probiotics consensus statement. *Nat Rev Gastroenterol Hepatol*. 2014.
36. Hooper LV, Littman DR, Macpherson AJ. Microbiota–immune interactions. *Science*. 2012;336:1268–1273.
37. Hughes SA, Shewry PR, Li L, et al. In vitro fermentation of wheat arabinoxylans. J Agric Food Chem. 2007;55:4589–4595.
38. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–214.
39. Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature. 2019;569:641–648.
40. Jian X, et al. LPS-mediated inflammation and metabolic disease. Front Immunol. 2025;16:1–12.
41. Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerosis. Nat Commun. 2017;8:845.
42. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy in autism. *Sci Rep*. 2019;9:1–13.

DOI: 10.46121/pspc.54.2.14

43. Khalesi S, Sun J, Buys N, Jayasinghe R. Probiotics and cardiovascular risk factors. Hypertension. 2019;73:1–10.
44. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220–229.
45. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. Microbial metabolites in host metabolism. *Cell Metab*. 2022;34:1–15.
46. Lavelle A, Sokol H. Gut microbiota-derived metabolites in inflammation. *Microbiome*. 2020;8:1–15.
47. Li J, Jia H, Cai X, et al. Multi-omics analysis of gut microbiome in human health and disease. Nat Rev Gastroenterol Hepatol. 2024;21:1–15.
48. Liu Y, et al. Microbiota and adipokine regulation. J Clin Endocrinol Metab. 2025;110:1–12.
49. Makki K, Deehan EC, Walter J, Bäckhed F. Dietary fiber and gut microbiota. *Cell Host Microbe*. 2018;23(6):705–715.
50. Markowiak P, Śliżewska K. Effects of probiotics and prebiotics. Nutrients. 2017;9:1021.
51. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37:47–55.
52. McFarland LV. Systematic review of Saccharomyces boulardii. World J Gastroenterol. 2010;16:2202–2222.
53. Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention and microbiota. *Gut Microbes*. 2020;11:1–14.
54. Morais LH, Schreiber HL, Mazmanian SK. Gut microbiota–brain axis. *Nat Rev Microbiol*. 2021;19:241–255.
55. Nishiwaki H, Ito M, Ishida T, et al. Gut microbiota in Parkinson's disease. *npj Parkinsons Dis*. 2020;6:1–10.
56. Niu Y, et al. Synbiotics in obesity. Clin Nutr. 2024;43:1–10.
57. O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics. *Nat Rev Gastroenterol Hepatol*. 2023.
58. Ooijevaar RE, Terveer EM, Verspaget HW, et al. Clinical application and potential of fecal microbiota transplantation. Gastroenterology. 2019;156:1123–1137.
59. Ouwehand AC, Salminen S, Isolauri E. Probiotics: mechanisms of action. Int Dairy J. 2002;12:595–608.
60. Pan X, et al. Synbiotics in NAFLD: clinical evidence. Clin Nutr. 2024;43:1–10.
61. Parada Venegas D, De la Fuente MK, Landskron G, et al. SCFAs and gut health. *Front Immunol*. 2019;10:277.
62. Pinto-Sánchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum and depression. Gastroenterology. 2017;153:448–459.
63. Qin J, Li Y, Cai Z, et al. Gut microbiome in type 2 diabetes. Nature. 2012;490:55–60.
64. Rasaei N, et al. Synbiotics in obesity: systematic review. Obes Rev. 2024;25:e13500.
65. Romani M, Pistillo F, Banfi G. Gut microbiota and Alzheimer's disease. *Front Aging Neurosci*. 2021;13:1–15.
66. Salamat S, et al. Synbiotics and cardiometabolic risk. Nutr Metab Cardiovasc Dis. 2024;34:1–9.

DOI: 10.46121/pspc.54.2.14

67. Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits in Parkinson's disease. Cell. 2016;167:1469–1480.
68. Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics update. *Nat Rev Gastroenterol Hepatol*. 2023;20:15–33.
69. Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health. Nat Rev Gastroenterol Hepatol. 2019;16:605–616.
70. Schwabe RF, Jobin C. Microbiome and cancer. *Nat Rev Cancer*. 2023;23:1–15.
71. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of NAFLD/NASH. *Nat Rev Gastroenterol Hepatol*. 2020.
72. Scorletti E, Afolabi PR, Miles EA, et al. Synbiotics in NAFLD. Hepatology. 2020;71:1–13.
73. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacterial cells. *PLoS Biol*. 2016;14(8):e1002533.
74. Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. *Nature*. 2021;579:567–574.
75. Shaaban SY, El Gendy YG, Mehanna NS, et al. Probiotics in autism spectrum disorder. *Nutrients*. 2020;12:1–12.
76. Sharon G, Cruz NJ, Kang DW, et al. Gut microbiota and ASD. *Cell*. 2019;177:1600–1618.
77. Sharpton SR, Ajmera V, Loomba R. Gut microbiome in NAFLD. *Nat Rev Gastroenterol Hepatol*. 2019.
78. Simpson HL, Campbell BJ. Review article: dietary fibre–microbiota interactions. Aliment Pharmacol Ther. 2021;53(2):229–243.
79. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5:1417–1435.
80. Socała K, Doboszewska U, Szopa A, et al. Microbiota in neurological disorders. *Pharmacol Rep*. 2021;73:1–15.
81. Sun L, Xie C, Wang G, et al. Gut microbiota and bile acid metabolism. *Diabetes Care*. 2021;44:1–10.
82. Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on prebiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687–701.
83. Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–1584.
84. Tilg H, Adolph TE, Moschen AR. NAFLD and the gut microbiome. *Nat Rev Gastroenterol Hepatol*. 2020;17:1–15.
85. Tilg H, Moschen AR. Microbiota and NAFLD. Gut. 2014;63:550–559.
86. Tripathi A, Debelius J, Brenner DA, et al. The gut–liver axis. *Hepatology*. 2018;67:1–15.
87. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome. Nature. 2006;444:1027–1031.
88. Valdes AM, Walter J, Segal E, Spector TD. Role of diet in shaping gut microbiota. *BMJ*. 2020;361:k2179.
89. Wang M, Wan J, Rong H, et al. Gut microbiota in autism. *Front Microbiol*. 2022;13:1–15.
90. Westfall S, Lomis N, Kahouli I, et al. Microbiome-based therapies. *Front Neurosci*. 2021;15:1–14.

DOI: 10.46121/pspc.54.2.14

91. Wong SH, Yu J. Gut microbiota in colorectal cancer. *Nat Rev Gastroenterol Hepatol*. 2023;20:1–17.
92. Zhang YJ, Li S, Gan RY, et al. Impacts of gut microbiota on human health. *Signal Transduct Target Ther*. 2021;6:135.
93. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity. *Immunity*. 2020;52(1):35–54.
94. Zinöcker MK, Lindseth IA. The Western diet–microbiome-host interaction and its role in metabolic disease. Nutrients. 2018;10:365.
95. Zmora N, Suez J, Elinav E. Personalized microbiome-based nutrition. *Cell*. 2019;178:1067–1080.

DOI: 10.46121/pspc.54.2.14